[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69409633D1 - Transdermal behandlung von krebs mit wasserunlöslichem s-camtothecin mit geschlossenem lactoring - Google Patents

Transdermal behandlung von krebs mit wasserunlöslichem s-camtothecin mit geschlossenem lactoring

Info

Publication number
DE69409633D1
DE69409633D1 DE69409633T DE69409633T DE69409633D1 DE 69409633 D1 DE69409633 D1 DE 69409633D1 DE 69409633 T DE69409633 T DE 69409633T DE 69409633 T DE69409633 T DE 69409633T DE 69409633 D1 DE69409633 D1 DE 69409633D1
Authority
DE
Germany
Prior art keywords
camptothecin
insoluble
water
closed
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69409633T
Other languages
English (en)
Other versions
DE69409633T2 (de
Inventor
Beppino C Giovanella
Hellmuth R Hinz
Anthony J Kozielski
John S Stehlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stehlin Foundation for Cancer Research
Original Assignee
Stehlin Foundation for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stehlin Foundation for Cancer Research filed Critical Stehlin Foundation for Cancer Research
Application granted granted Critical
Publication of DE69409633D1 publication Critical patent/DE69409633D1/de
Publication of DE69409633T2 publication Critical patent/DE69409633T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69409633T 1993-01-15 1994-01-14 Transdermal behandlung von krebs mit wasserunlöslichem s-camtothecin mit geschlossenem lactoring Expired - Fee Related DE69409633T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US284493A 1993-01-15 1993-01-15
PCT/US1994/000403 WO1994015604A1 (en) 1993-01-15 1994-01-14 Transdermal treatment of cancer with water-insoluble s-camptothecin of the closed lactone ring form

Publications (2)

Publication Number Publication Date
DE69409633D1 true DE69409633D1 (de) 1998-05-20
DE69409633T2 DE69409633T2 (de) 1998-08-06

Family

ID=21702794

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69431731T Expired - Fee Related DE69431731T2 (de) 1993-01-15 1994-01-14 Orale oder intramuskuläre Behandlung von Pankreaskrebs durch wasserunlösliches S-Camptothecin mit geschlossenem Lactonring
DE69409633T Expired - Fee Related DE69409633T2 (de) 1993-01-15 1994-01-14 Transdermal behandlung von krebs mit wasserunlöslichem s-camtothecin mit geschlossenem lactoring
DE69435084T Expired - Fee Related DE69435084T2 (de) 1993-01-15 1994-01-14 Die Verwendung von wasserunlöslichem S-Camptothecin mit geschlossenem Lactonring für die Herstellung eines Medikamentes zur Behandlung von Darmkrebs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69431731T Expired - Fee Related DE69431731T2 (de) 1993-01-15 1994-01-14 Orale oder intramuskuläre Behandlung von Pankreaskrebs durch wasserunlösliches S-Camptothecin mit geschlossenem Lactonring

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69435084T Expired - Fee Related DE69435084T2 (de) 1993-01-15 1994-01-14 Die Verwendung von wasserunlöslichem S-Camptothecin mit geschlossenem Lactonring für die Herstellung eines Medikamentes zur Behandlung von Darmkrebs

Country Status (9)

Country Link
EP (3) EP0678025B1 (de)
JP (1) JP3099128B2 (de)
AT (3) ATE165003T1 (de)
CA (1) CA2148822C (de)
DE (3) DE69431731T2 (de)
DK (3) DK0678025T3 (de)
ES (3) ES2114681T3 (de)
PT (1) PT1250926E (de)
WO (1) WO1994015604A1 (de)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244903A (en) * 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
ATE211142T1 (de) * 1989-09-15 2002-01-15 Res Triangle Inst Verfahren zur herstellung von 10,11-methylendioxy-20(rs)-camptothecin und 10,11-methylendioxy-20(s)-camptothecin-analog
US5422344A (en) * 1990-05-08 1995-06-06 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Method of treating retroviral infections in mammals
DE69209969T2 (de) * 1991-10-29 1996-09-12 Glaxo Wellcome Inc Wasserlösliche Camptothecinderivate
EP0612248B1 (de) * 1991-11-15 2003-08-20 Smithkline Beecham Corporation Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor.
EP0661977A1 (de) * 1991-12-10 1995-07-12 Smithkline Beecham Corporation Behandlung von kolorektaler krebs

Also Published As

Publication number Publication date
EP1250926A3 (de) 2002-11-20
ATE227573T1 (de) 2002-11-15
EP0778024A1 (de) 1997-06-11
DE69435084T2 (de) 2009-03-19
CA2148822A1 (en) 1994-07-21
DE69435084D1 (de) 2008-04-24
JP3099128B2 (ja) 2000-10-16
DE69409633T2 (de) 1998-08-06
DK0678025T3 (da) 1998-10-07
ATE388706T1 (de) 2008-03-15
ATE165003T1 (de) 1998-05-15
DE69431731D1 (de) 2002-12-19
EP1250926A2 (de) 2002-10-23
DE69431731T2 (de) 2003-03-13
EP1250926B1 (de) 2008-03-12
CA2148822C (en) 2001-03-27
EP0678025B1 (de) 1998-04-15
EP0678025A1 (de) 1995-10-25
DK1250926T3 (da) 2008-07-07
ES2301590T3 (es) 2008-07-01
PT1250926E (pt) 2008-06-11
EP0778024B1 (de) 2002-11-13
WO1994015604A1 (en) 1994-07-21
JPH08505626A (ja) 1996-06-18
DK0778024T3 (da) 2002-12-23
ES2114681T3 (es) 1998-06-01
ES2186812T3 (es) 2003-05-16

Similar Documents

Publication Publication Date Title
DE3776946D1 (de) Nasale verabreichung von arzneimitteln.
DE59102210D1 (de) Galanthemin enthaltende pharmazeutische Formulierung zur Behandlung des Alkoholismus.
DE69409633D1 (de) Transdermal behandlung von krebs mit wasserunlöslichem s-camtothecin mit geschlossenem lactoring
DE69010523D1 (de) Kit oder Zusammensetzung zur Vorbeugung oder Behandlung von HIV-1 Infektionen.
DE69233773D1 (de) Verwendung von topotecan zur herstellung eines medikaments zur verwendung in der behandlung von ovarialkrebs
ATE152911T1 (de) Verwendung von bilobalid und deren derivate zur behandlung von infektionen bei menschen und für eine solche anwendung geeignete pharmazeutische zusammensetzung
DE69932741D1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
NO890261D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetrahydropyridin-derivater.
AU628492B2 (en) Improvements in chemical compounds
ATE163264T1 (de) Verwendung von n,n'-bis 3-(ethylamino)propyl-1,7- heptandiamin und einem zytotoxischen mittel
DE69001988D1 (de) Behandlung des schocks mit cyclodextrin und dessen derivaten.
ATE59776T1 (de) Pharmazeutische zusammensetzung und behandlung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee